Replies to post #448944 on NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

NASA has not returned to the Moon since the 1970’s. Mars has become a pipe dream. We have exactly one space station we have to share with other countries. Not a good comparison.

I was invested back when this stock was 10 bucks a share and going and staying below $1 after this many months after data lock would have been unthinkable.

[skitahoe]

At this point I believe it's a little late to be talking about perfection, the trial has completed, the results are in, it's all about having them stated in a manner that's understood to be a major advancement in the treating of GBM, and perhaps eventually many solid cancers.
.
We shouldn't be afraid of looking at the data, we don't need excuses, we know that far more people lived longer, or remain alive today, than ever could have been expected with the SOC. Sure, knowing what we do today if we ran the trial again it would be run differently. I suspect that if we were starting from scratch we'd use one of the protocols being run at UCLA and improve the outcome even more. Given what was known when the trial began, the outcome is excellent.

I doubt if 90% of newly approved therapeutics are used precisely the way the trial protocol was run. New discoveries are made all the time, and pivotal trials take many years to run, by the time they're over, there are better ways of using the products.

If the trial were initiated today, surgery would be improved, all patients would get the vaccine up front, no cross overs, I don't know that over 40% wouldn't be alive after 5 years. Add Keytruda, etc. and the number might grow to 50 to 70%, we really don't know without further trials. The key is, take away DCVax-L, and perhaps the 5 year survival that has been under 5% on the SOC only increases to 10 to perhaps 15%, it's DCVax-L that's making the big difference.

Lets not fear the data, lets get it out. If the findings show that certain groups got much greater benefit, people like Dr. Liau will be working all the harder to find what will benefit those who aren't getting that much benefit from the vaccine as is.

I've seen many companies fight for approval of products that appeared to have patients living months longer, and they won. We have a product that is permitting 2, 3, 4 or more times the number of patients to live 5 years or longer, we have nothing to apologize for. Nothing is ever certain with the regulators, but this should be a slam dunk.

I don't doubt that the data is complicated, even the definition of what is GBM has changed since the trial began. IDH was an unknown when the trial began, as was pseudoprogression, much else has changed as well, but SOC treatment hasn't changed that much, and many are still dying, far too many.

Gary